houseStanding
Energy and Commerce Committee
- Referred To
← Back to federal legislation
H.R. 1843In committee
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Introduced: Mar 5, 2025
Latest action date: Mar 5, 2025
Latest development
Referred to the House Committee on Energy and Commerce.
Your view
- Congress
- 119th Congress
- Introduced
- Mar 5, 2025
- Recorded roll calls
- 0
Status detail: The most advanced recorded stage is committee consideration.
Plain-language overview
What this bill does
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
Civixly topics
What this legislation is about
Civixly topics make federal and state legislation comparable. They are derived from the official CRS policy area and legislative subjects.
Official CRS policy area
Health
Committee activity
Committees and subcommittees that received, reviewed, marked up, or reported this legislation.
Official committee record ↗
Amendments
Proposed changes to this measure, with their latest official outcome or action from Congress.gov.
No amendments are listed for this measure.
Checked against Congress.gov Sep 15, 2026.
Action timeline
Newest action first. Action language comes from the official Congress.gov record.
View full action timeline3 actions
Introduced in House
IntroReferralLibrary of CongressReferred to the House Committee on Energy and Commerce.
IntroReferralHouse floor actionsIntroduced in House
IntroReferralLibrary of Congress
Roll-call votes
Recorded House and Senate votes connected to this bill. Your representatives appear first when available.
No connected roll-call votes are currently available for this bill.
Discussion
0 comments
Sign in to join the discussion.Comments are publicly visible.
Loading comments...